Trial reportScientific reports2026
Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the real world, there are variable treatment strategies and therapeutic effects of anti-VEGF therapy in neovascular age-related macular degeneration (nAMD). To investigate mechanisms of fluid resolution in pretreated and treatment-naïve eyes, we aimed to compare treatment response through assessment of fluid types, distribution and volumes. 289 eyes of 289 real-world patients with active nAMD were included in a randomized phase III clinical trial (EudraCT-Number: 2019-003133-42). For this subanalysis, data from baseline and month 1 was collected in 285 eyes. All eyes received treatment at baseline, OCT imaging (Spectralis, Heidelberg Engineering, Germany) and standardized functional testing at both visits. Subretinal fluid (SRF), intraretinal fluid (IRF), pigment epithelial detachment (PED) were automatically quantified. Absolute and relative fluid resolution and BCVA changes were compared. Treatment-naïve eyes had higher IRF volumes before treatment and a higher reduction of IRF (p < 0.01), with no differences for SRF and PED. Accordingly, treatment-naïve patients had a significantly higher gain of BCVA with + 4.6 letters compared to + 1.2 letters (p < 0.01). Precise quantification and compartment distinctions of retinal fluid revealed treatment-naïve eyes showed greater resolution rates for IRF with consecutive significant visual improvement, suggesting that IRF dynamics are particularly relevant and volume-related, especially in the acute phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.